Sudden infant death syndrome and secretin treatment for autism.
The Back to Sleep Campaigns remain the greatest influence on the reduction of sudden infant death syndrome. Blatt and Meguid review updates on the effectiveness of these campaigns in reducing sudden infant death syndrome. They also review studies on why parents do not follow this proven advice. The contribution of the risks of other environmental factors are also reviewed. Also discussed are commentaries from a study reviewed last on the link between a prolonged QT electrocardiogram interval and sudden infant death syndrome. Church provides a cogent and timely review of the reported effectiveness of hormone secretin effectiveness in treating children with autism. This newly proposed treatment has been in the spotlight of the lay public, the popular media, and the scientific community. In short order, secretin as a treatment for autism has moved from a chance observation to the subject of a double-blind, placebo-controlled study.
Blatt
S D
SD
Upstate Medical University, State University of New York, Syracuse 13202, USA.
Meguid
V
V
Church
C C
CC
D001321:Autistic Disorder / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008133:Long QT Syndrome / Q000150:complications; D012633:Secretin / Q000627:therapeutic use; D013398:Sudden Infant Death / Q000517:prevention & control*; D016683:Supine Position; D016896:Treatment Outcome
D012633:Secretin